Biomerica Reports Fiscal 2021 1st Quarter Financial Results - Seite 2
“International demand for our disposable point-of-care antibody test decreased during the quarter. I believe this decrease was due in part from a lower daily infection rate during the summer months in the international markets in which we operate, as well as an increase in customer focus on virus testing (PCR and antigen tests). Importantly, as we enter the fall and winter months, the daily rate of new infections is rising, and the number of persons who have been infected by COVID-19 continues to increase, we are seeing increases in demand for both antigen and antibody tests. In addition, I am encouraged to see revenues of our non-COVID related products, which have been negatively affected by the pandemic, now starting to recover,” concluded Mr. Irani.
About Biomerica (NASDAQ:)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets
advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical
conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on gastrointestinal
and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
Lesen Sie auch
About InFoods
The Biomerica InFoods IBS product is designed to allow physicians to identify patient specific foods (e.g. eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may
alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to
allow for a patient specific, guided dietary regimen to improve IBS outcomes. The point-of-care product is being developed to allow physicians to perform the test in-office using a finger stick
blood sample while a clinical lab version of the product is expected to be the first for which the company will seek regulatory approval. A billable CPT code that can be used by both clinical labs
and physicians' offices is already available for InFoods diagnostic products. Since the InFoods product is a diagnostic-guided therapy, and not a drug, it has no drug type side effects. An
estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits.